Genmab A/S (NASDAQ:GMAB) Announces Earnings Results

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings data on Tuesday. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41), Zacks reports. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab reported 2025 revenue of $3.7 billion (up 19%) and expanded operating profit to $1.26 billion, while guiding 2026 revenue growth around the midpoint of 14% and targeting gross leverage below 3x by end-2027.
• Commercial momentum accelerated: proprietary medicines totaled $632 million (up 54%), with Epkinly at $468 million (+67%) and Tivdak $164 million (+26%), and Epkinly now approved in >65 countries as Genmab expands direct commercialization in Europe, Japan and the U.S.
• The Merus acquisition added petosemtamab, giving Genmab three late‑stage programs (Epkinly, Rina‑S, petosemtamab) with five breakthrough designations that management says have multi‑billion dollar potential.
• The EPCORE DLBCL‑1 Phase III of Epkinly showed a PFS benefit but missed statistical significance for overall survival, and Genmab will discuss next steps with regulators while asserting other Phase III trials remain viable as confirmatory evidence.
• 2026 is framed as a catalyst year with up to six potentially registrational readouts (including frontline and second‑line Epkinly combos, a Rina‑S readout in PROC, and one or both petosemtamab Phase IIIs), which could set the stage for multiple 2027 launches.

Genmab A/S Stock Performance

Shares of GMAB stock traded down $0.74 during trading hours on Wednesday, hitting $29.27. 1,196,801 shares of the company were exchanged, compared to its average volume of 1,777,532. Genmab A/S has a one year low of $17.24 and a one year high of $35.43. The business’s 50-day simple moving average is $32.30 and its two-hundred day simple moving average is $29.88. The stock has a market capitalization of $18.80 billion, a price-to-earnings ratio of 12.47, a P/E/G ratio of 17.63 and a beta of 0.90.

Wall Street Analysts Forecast Growth

GMAB has been the topic of a number of recent research reports. Morgan Stanley started coverage on Genmab A/S in a research note on Monday. They set an “equal weight” rating and a $34.00 price objective on the stock. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Finally, Jefferies Financial Group assumed coverage on shares of Genmab A/S in a report on Tuesday. They issued a “buy” rating and a $41.50 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.30.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after buying an additional 1,174 shares during the period. Sei Investments Co. grew its holdings in shares of Genmab A/S by 4.2% during the second quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after purchasing an additional 2,496 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after purchasing an additional 81,434 shares during the last quarter. Quantinno Capital Management LP raised its position in shares of Genmab A/S by 64.9% during the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock worth $3,267,000 after purchasing an additional 62,226 shares during the period. Finally, Raymond James Financial Inc. lifted its holdings in shares of Genmab A/S by 48.1% in the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock worth $643,000 after purchasing an additional 10,113 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company announced a targeted share buy‑back to repurchase up to 342,130 shares (max ~725 million DKK) to satisfy Restricted Stock Unit obligations; program completes by March 31, 2026 — reduces share count and supports EPS. Article Title
• Positive Sentiment: Analyst momentum: HC Wainwright raised its target to $40 (buy) and Jefferies initiated coverage with a $41.50 buy target; Morgan Stanley also began coverage and broker consensus is a “Moderate Buy” — these lifts can attract demand and support higher valuations. Article Title Article Title Article Title
• Neutral Sentiment: Reported Q4 operationals showed strong revenue (~$1.06B) and company commentary highlighted revenue growth and strategic expansion; mixed readthrough on profitability as some sources differ on exact EPS beats. Investors will focus on underlying revenue growth and guidance cadence. Article Title Article Title
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the SEC — provides updated financials, strategy commentary and the company’s outlook for 2026; useful for longer‑term modeling but not an immediate catalyst. Article Title Article Title
• Neutral Sentiment: Notice of Annual General Meeting set for March 19, 2026 — routine corporate governance item; potential minor share‑holder/board impacts depending on votes. Article Title
• Neutral Sentiment: Reported short‑interest data in the feed appears inconsistent/unreliable (NaN/zero entries) — no clear short‑pressure signal from this update. (Data quality flag.)
• Negative Sentiment: An earnings call transcript published by a third party shows a reported EPS figure below expectations (one transcript notes $0.4035 vs ~$0.46 est.), which could explain some intra‑day selling or caution; note there are conflicting EPS figures across sources, so market reaction may reflect uncertainty. Article Title

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.